Cellmid (ASX: CDY) has appointed biotechnology veteran Graeme Kaufman as non-executive director.
Kaufman brings more than 45 years of hands on experience in biotechnology spanning technical, commercial and financial areas.
Having worked for 34 years at CSL Limited (ASX: CSL), Australia’s largest biopharmaceutical company, he held senior positions including production director, general manager finance and general manager biosciences.
Kaufman’s responsibilities at CSL included corporate strategy and development as well as manufacturing, finance and marketing.
He was instrumental in the privatisation and ASX listing of CSL, including the negotiation of key contracts with stakeholders prior to listing.
Kaufman was formerly executive director of Circadian Technologies (ASX: CIR) and most recently senior vice president of corporate strategy at Mesoblast (ASX: MSB).
David King, chairman of Cellmid, commented: “Graeme has been an adviser to our senior management team for some years and has intimate knowledge of the midkine asset portfolio.”
Meanwhile, Robin Beaumont, who was appointed to the Board of Cellmid on 12 October 2009, has stepped down as non-executive director.
Cellmid recently secured a commercially important midkine protein patent in the United States. The patent is key to the company’s program for the treatment of various forms of ischemia including heart attack.
The company holds the most significant intellectual property portfolio related to midkine worldwide, increasing commercialisation opportunities.
Cellmid’s target in commercialising midkine related technology is to develop the products to some extent then out licence/partner.
The company is in discussion with multiple partners in relation to both its diagnostic and therapeutic assets.
Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.